CoChat

HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer

Open access
Takegawa, Naoki, Yonesaka, Kimio, Sakai, Kazuko, Ueda, Hiroto, Watanabe, Satomi, Nonagase, Yoshikane, Okuno, Tatsuya, Takeda, Masayuki, Maenishi, Osamu, Tsurutani, Junji, Satoh, Taroh, Okamoto, Isamu, Nishio, Kazuto, Tamura, Takao, Nakagawa, Kazuhiko · 2016 · Oncotarget
Cited by 70

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

// Naoki Takegawa 1 , Kimio Yonesaka 1 , Kazuko Sakai 2 , Hiroto Ueda 1 , Satomi Watanabe 1 , Yoshikane Nonagase 1 , Tatsuya Okuno 1 , Masayuki Takeda 1 , Osamu Maenishi 3 , Junji Tsurutani 1 , Taroh Satoh 4 , Isamu Okamoto 5 , Kazuto Nishio 2 , Takao Tamura 1 , and Kazuhiko Nakagawa 1 1 Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan 2 Department of Genome Biology, Kinki University School of Medicine, Osaka, Japan 3 Department of Pathology, Kinki University School of Medicine, Osaka, Japan 4 Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Osaka, Japan 5 Center for Clinical and Translational Research, Kyushu University, Kyushu, Japan Correspondence to: Kimio Yonesaka, e-mail: yonesaka@sakai.med.kindai.ac.jp Keywords: colorectal cancer, cetuximab, acquired resistance, human epidermal growth factor receptor 2, ctDNA Received: August 21, 2015 Accepted: November 21, 2015 Published: December 02, 2015 ABSTRACT Background: Patients with metastatic colorectal cancer (mCRC) harboring wild-type KRAS benefit from epidermal growth factor receptor (EGFR)-targeted therapy. However, patients who are treated with anti-EGFR antibodies will eventually develop the resistance to those agents. HER2 amplification is one of the mechanisms conferring resistance to anti-EGFR antibody therapy and could therefore be a potential therapeutic target. The aim of this study was to detect HER2 amplification in circulating tumor DNA (ctDNA) from patients with CRC and acquired resistance to anti-EGFR antibody therapy. Results: Our data showed that 22% (4/18) of patients in the cohort exhibited HER2 amplification. One of these patients was found to be positive for HER2 amplification in matched tumor specimens collected after cetuximab therapy, at which point the patient had acquired cetuximab resistance, despite being negative for HER2 amplification prior to therapy. Methods: We analyzed plasma ctDNA using digital polymerase chain reaction (PCR) from 18 patients with CRC, who had been treated with anti-EGFR antibody-based therapy (cetuximab) and subsequently acquired resistant cetuximab. HER2 gene copy number was analyzed using fluorescence in situ hybridization in tumor samples before and after acquisition of resistance to cetuximab-based therapy. Conclusion: Analysis of plasma ctDNA by digital PCR could be useful for detecting HER2 amplification in patients with CRC who were resistant to anti-EGFR antibody therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.6498

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

Metadata

Authors
Takegawa, N., Yonesaka, K., Sakai, K., Ueda, H., Watanabe, S., Nonagase, Y., Okuno, T., Takeda, M., Maenishi, O., Tsurutani, J., Satoh, T., Okamoto, I., Nishio, K., Tamura, T., & Nakagawa, K.
Venue
Oncotarget
Published
2015-12-02
Volume
7
Issue
3
Pages
3453-3460
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2220166442
Cited by
70
References
9
FWCI
2.86
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.